Recently, the pharmacologic suppression of hepcidin has been shown to increase the expression of ABCA1 and ABCG1 and lipid efflux via the macrophage-specific expression of cholesterol efflux transporters and to reduce foam cell formation and atherosclerosis in vivo and vitro [12]. The gene discussed is ABCG1; the disease is atherosclerosis.